Triplet therapy combinations involving a BTKi, a BCL2 inhibitor and CD20-targeting mAbs represent a promising therapeutic strategy for CLL still under investigation, especially for those patients harboring high-risk markers such as TP53 abn or CK, in which it is hard to achieve sustained uMRD4 remission. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.